Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4353 - Financial toxicity in patients with neuroendocrine tumors – impact of a chronic disease on patients’ economic situation


10 Sep 2017


Poster display session


Bioethical Principles and GCP;  Neuroendocrine Tumours


Leonidas Apostolidis


Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368


L. Apostolidis1, K. Mehlis1, M. Kudlich1, J. Witte2, J. Walther1, W. Greiner2, E.C. Winkler1

Author affiliations

  • 1 Department Of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, 69120 - Heidelberg/DE
  • 2 Department Of Health Economics And Health Care Management, School of Public Health, Bielefeld University, 33615 - Bielefeld/DE


Abstract 4353


The diagnosis of cancer imposes physical, emotional and financial burdens on patients. So far, the socio-economic impact of cancer for patients in Germany is poorly understood. The aim of the project is to provide an overview on patients' financial losses due to a neuroendocrine tumor (NET) diagnosis as well as possible psychosocial effects.


This prospective quantitative study recruited n = 123 patients with NET from November 2016 to March 2017 at the National Center for Tumor Diseases, University Hospital Heidelberg. They completed a survey on patients' income, cancer-related out-of-pocket costs, disease burden (Distress Thermometer), quality of life (EORTC-LQ 29/30), health status (EQ-5D) and demographic data.


78.0% (n = 96) of the patients stated to have higher out-of-pocket costs because of their disease, mostly in terms of travel expenses and co-payments for medication. With regard to loss of income, 29.3% (n = 36) of the participants reported a minus, which is beyond 800€per month in almost half (44.4%) of these cases. 61.5% of the persons affected by income losses cannot compensate these by savings or credits. 33.3% (n = 41) of the responding patients indicated that they have to cut back on their expenses of daily living as a result of their disease. Higher cancer-related out-of-pocket costs per month were associated with lower estimation of patient's quality of life (p = 0.003), lower self-reported health status (p = 0.013) and a more severe perception of disease burden (p = 0.036) whereas a higher monthly income was strongly correlated with better quality of life (p=.008)/health status (p = 0.008) and lower disease burden (p = 0.006).


Given the fact that the majority of surveyed patients has to face financial losses due to their cancer diagnosis which is accompanied by the experience of distress as well as worsened quality of life and health status, there is a need for targeted measures that could prevent financial problems and reduce emotional burdens. Further research is required to address this aim.

Clinical trial identification

The trial was approved by the Instituional Research Ethics Committee (approval S-458/2016).

Legal entity responsible for the study

National Center for Tumor Diseases, University Hospital Heidelberg


Ipsen Pharma GmbH


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.